Platelet microvesicles are associated with the severity of coronary artery disease: comparison between peripheral and coronary circulation.
Eugenia GkaliagkousiE GavriilakiE YiannakiI VasileiadisB NikolaidouA LazaridisP DolgyrasS GrigoriadisA TriantafyllouP AnyfantiD MarkalaI ZarifisS DoumaPublished in: Journal of thrombosis and thrombolysis (2020)
Microvesicles (MVs) have recently emerged as markers of thrombosis. Furthermore, there is an unexplained residual thrombotic risk is observed in patients with acute coronary syndrome (ACS) and/or stable coronary artery disease (CAD), despite treatment. We measured platelet (PMVs) and erythrocyte (ErMVs) in patients with ACS and stable CAD, both in the peripheral and coronary circulation. We studied consecutive eligible patients during a coronary angiography. Blood samples were collected from the stem of the left coronary artery and femoral artery. PMVs were significantly increased in CAD patients compared to controls. ACS patients had also increased PMVs in coronary and peripheral circulation, compared to controls. Furthermore, ACS patients exhibited increased PMVs in coronary compared to peripheral circulation. Lastly, coronary PMVs were associated with the severity of CAD based on the SYNTAX score. No significant differences were observed in the levels of ErMVs among groups. Therefore, PMVs emerge as novel markers of thrombosis in CAD, further augmenting the vicious cycle of inflammation and thrombosis during ACS. Importantly, coronary PMVs may reflect the severity of CAD in this population.
Keyphrases
- coronary artery disease
- coronary artery
- end stage renal disease
- ejection fraction
- newly diagnosed
- percutaneous coronary intervention
- cardiovascular events
- prognostic factors
- aortic stenosis
- pulmonary artery
- type diabetes
- cardiovascular disease
- oxidative stress
- pulmonary embolism
- patient reported outcomes
- replacement therapy